Does the media refer more to RYTM or NUVB?

In the previous week, Nuvation Bio had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 5 mentions for Nuvation Bio and 3 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.14 beat Nuvation Bio's score of 0.60 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvation Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NUVB or MIRM?

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than Nuvation Bio. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 5 mentions for Nuvation Bio. Mirum Pharmaceuticals' average media sentiment score of 0.78 beat Nuvation Bio's score of 0.60 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NUVB or SYRE?

In the previous week, Nuvation Bio and Nuvation Bio both had 5 articles in the media. Spyre Therapeutics' average media sentiment score of 1.03 beat Nuvation Bio's score of 0.60 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, NUVB or LNTH?

Lantheus has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvation Bio $62.90M 31.97 -$204.63M -$0.43 N/A Lantheus $1.54B 4.45 $233.56M $4.15 25.40

Is NUVB or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Nuvation Bio's net margin of -102.06%. Lantheus' return on equity of 29.32% beat Nuvation Bio's return on equity. Company Net Margins Return on Equity Return on Assets Nuvation Bio -102.06% -44.10% -23.80% Lantheus 18.05% 29.32% 15.00%

Does the media prefer NUVB or LNTH?

In the previous week, Nuvation Bio had 1 more articles in the media than Lantheus. MarketBeat recorded 5 mentions for Nuvation Bio and 4 mentions for Lantheus. Lantheus' average media sentiment score of 1.19 beat Nuvation Bio's score of 0.60 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NUVB or PTCT?

In the previous week, PTC Therapeutics had 12 more articles in the media than Nuvation Bio. MarketBeat recorded 17 mentions for PTC Therapeutics and 5 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.60 beat PTC Therapeutics' score of 0.57 indicating that Nuvation Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Nuvation Bio (NUVB) Competitors

$5.78 -0.04 (-0.60%)

Closing price 07/13/2026 03:59 PM Eastern

Extended Trading

$5.74 -0.03 (-0.52%)

As of 07/13/2026 07:59 PM Eastern

Compare

NUVB vs. RYTM, MIRM, SYRE, LNTH, and PTCT

Should you buy Nuvation Bio stock or one of its competitors? MarketBeat compares Nuvation Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvation Bio include Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), Spyre Therapeutics (SYRE), Lantheus (LNTH), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry.

How does Nuvation Bio compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Nuvation Bio (NYSE:NUVB) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

61.7% of Nuvation Bio shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 30.1% of Nuvation Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Nuvation Bio had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 5 mentions for Nuvation Bio and 3 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.14 beat Nuvation Bio's score of 0.60 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvation Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Nuvation Bio's net margin of -102.06%. Nuvation Bio's return on equity of -44.10% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Nuvation Bio	-102.06%	-44.10%	-23.80%

Rhythm Pharmaceuticals has higher revenue and earnings than Nuvation Bio. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	38.82	-$196.54M	-$3.13	N/A
Nuvation Bio	$62.90M	31.97	-$204.63M	-$0.43	N/A

Rhythm Pharmaceuticals has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

Rhythm Pharmaceuticals presently has a consensus price target of $138.29, indicating a potential upside of 28.65%. Nuvation Bio has a consensus price target of $12.38, indicating a potential upside of 114.29%. Given Nuvation Bio's higher probable upside, analysts clearly believe Nuvation Bio is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Rhythm Pharmaceuticals and Nuvation Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does Nuvation Bio compare to Mirum Pharmaceuticals?

Nuvation Bio (NYSE:NUVB) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

Nuvation Bio currently has a consensus target price of $12.38, indicating a potential upside of 114.29%. Mirum Pharmaceuticals has a consensus target price of $143.40, indicating a potential upside of 20.46%. Given Nuvation Bio's higher probable upside, equities research analysts plainly believe Nuvation Bio is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Nuvation Bio has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than Nuvation Bio. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 5 mentions for Nuvation Bio. Mirum Pharmaceuticals' average media sentiment score of 0.78 beat Nuvation Bio's score of 0.60 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.7% of Nuvation Bio shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Mirum Pharmaceuticals has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	31.97	-$204.63M	-$0.43	N/A
Mirum Pharmaceuticals	$521.31M	13.92	-$23.36M	-$13.61	N/A

Nuvation Bio has a net margin of -102.06% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-102.06%	-44.10%	-23.80%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Summary

Mirum Pharmaceuticals beats Nuvation Bio on 10 of the 17 factors compared between the two stocks.

How does Nuvation Bio compare to Spyre Therapeutics?

Nuvation Bio (NYSE:NUVB) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Spyre Therapeutics has lower revenue, but higher earnings than Nuvation Bio. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	31.97	-$204.63M	-$0.43	N/A
Spyre Therapeutics	$890K	9,261.37	-$155.20M	-$2.08	N/A

Spyre Therapeutics has a net margin of 0.00% compared to Nuvation Bio's net margin of -102.06%. Spyre Therapeutics' return on equity of -42.88% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-102.06%	-44.10%	-23.80%
Spyre Therapeutics	N/A	-42.88%	-27.76%

61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Nuvation Bio presently has a consensus price target of $12.38, indicating a potential upside of 114.29%. Spyre Therapeutics has a consensus price target of $101.42, indicating a potential upside of 8.20%. Given Nuvation Bio's higher possible upside, research analysts plainly believe Nuvation Bio is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Nuvation Bio has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.02, suggesting that its share price is 202% more volatile than the broader market.

In the previous week, Nuvation Bio and Nuvation Bio both had 5 articles in the media. Spyre Therapeutics' average media sentiment score of 1.03 beat Nuvation Bio's score of 0.60 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Spyre Therapeutics beats Nuvation Bio on 10 of the 16 factors compared between the two stocks.

How does Nuvation Bio compare to Lantheus?

Nuvation Bio (NYSE:NUVB) and Lantheus (NASDAQ:LNTH) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

In the previous week, Nuvation Bio had 1 more articles in the media than Lantheus. MarketBeat recorded 5 mentions for Nuvation Bio and 4 mentions for Lantheus. Lantheus' average media sentiment score of 1.19 beat Nuvation Bio's score of 0.60 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvation Bio presently has a consensus target price of $12.38, indicating a potential upside of 114.29%. Lantheus has a consensus target price of $108.29, indicating a potential upside of 2.75%. Given Nuvation Bio's higher probable upside, analysts plainly believe Nuvation Bio is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Lantheus has a net margin of 18.05% compared to Nuvation Bio's net margin of -102.06%. Lantheus' return on equity of 29.32% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-102.06%	-44.10%	-23.80%
Lantheus	18.05%	29.32%	15.00%

61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lantheus has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	31.97	-$204.63M	-$0.43	N/A
Lantheus	$1.54B	4.45	$233.56M	$4.15	25.40

Nuvation Bio has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

Summary

Lantheus beats Nuvation Bio on 10 of the 15 factors compared between the two stocks.

How does Nuvation Bio compare to PTC Therapeutics?

Nuvation Bio (NYSE:NUVB) and PTC Therapeutics (NASDAQ:PTCT) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Nuvation Bio has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

PTC Therapeutics has a net margin of -22.58% compared to Nuvation Bio's net margin of -102.06%. Nuvation Bio's return on equity of -44.10% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-102.06%	-44.10%	-23.80%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

Nuvation Bio presently has a consensus price target of $12.38, indicating a potential upside of 114.29%. PTC Therapeutics has a consensus price target of $91.57, indicating a potential upside of 12.59%. Given Nuvation Bio's higher probable upside, equities analysts clearly believe Nuvation Bio is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80

61.7% of Nuvation Bio shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, PTC Therapeutics had 12 more articles in the media than Nuvation Bio. MarketBeat recorded 17 mentions for PTC Therapeutics and 5 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.60 beat PTC Therapeutics' score of 0.57 indicating that Nuvation Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

PTC Therapeutics has higher revenue and earnings than Nuvation Bio. PTC Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	31.97	-$204.63M	-$0.43	N/A
PTC Therapeutics	$1.73B	3.90	$682.64M	-$2.33	N/A

Summary

Nuvation Bio beats PTC Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Nuvation Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NUVB vs. The Competition

Export

Metric	Nuvation Bio	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$2.02B	$3.71B	$7.05B	$23.46B
Dividend Yield	N/A	2.20%	2.68%	4.02%
P/E Ratio	-13.43	20.85	27.11	31.08
Price / Sales	31.97	314.01	587.92	19.77
Price / Cash	N/A	61.98	29.22	18.64
Price / Book	6.56	8.49	10.75	4.77
Net Income	-$204.63M	$23.83M	$3.58B	$1.06B
7 Day Performance	1.76%	-3.56%	-2.06%	-0.23%
1 Month Performance	17.74%	6.31%	3.32%	-0.11%
1 Year Performance	168.11%	48.30%	26.36%	16.46%

Nuvation Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NUVB Nuvation Bio	3.3102 of 5 stars	$5.78 -0.6%	$12.38 +114.3%	+162.5%	$2.02B	$62.90M	N/A	60
RYTM Rhythm Pharmaceuticals	3.2622 of 5 stars	$111.68 -2.2%	$133.13 +19.2%	+24.0%	$7.82B	$189.76M	N/A	140	Positive News
MIRM Mirum Pharmaceuticals	2.5449 of 5 stars	$121.91 -2.9%	$143.00 +17.3%	+126.1%	$7.66B	$521.31M	N/A	140
SYRE Spyre Therapeutics	2.0156 of 5 stars	$88.74 +2.4%	$95.83 +8.0%	+497.4%	$7.62B	$890K	N/A	73	Positive News Analyst Forecast Gap Down
LNTH Lantheus	3.0926 of 5 stars	$102.82 -6.4%	$101.86 -0.9%	+29.6%	$7.15B	$1.54B	24.78	1,193	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NUVB) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvation Bio (NUVB) Competitors

NUVB vs. RYTM, MIRM, SYRE, LNTH, and PTCT

How does Nuvation Bio compare to Rhythm Pharmaceuticals?

Summary

How does Nuvation Bio compare to Mirum Pharmaceuticals?

Summary

How does Nuvation Bio compare to Spyre Therapeutics?

Summary

How does Nuvation Bio compare to Lantheus?

Summary

How does Nuvation Bio compare to PTC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVB vs. The Competition

Nuvation Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvation Bio (NUVB) Competitors

NUVB vs. RYTM, MIRM, SYRE, LNTH, and PTCT

How does Nuvation Bio compare to Rhythm Pharmaceuticals?

Do insiders & institutionals have more ownership in RYTM or NUVB?

Does the media refer more to RYTM or NUVB?

Is RYTM or NUVB more profitable?

Which has preferable valuation & earnings, RYTM or NUVB?

Which has more volatility & risk, RYTM or NUVB?

Do analysts rate RYTM or NUVB?

Summary

How does Nuvation Bio compare to Mirum Pharmaceuticals?

Do analysts rate NUVB or MIRM?

Which has more risk and volatility, NUVB or MIRM?

Does the media prefer NUVB or MIRM?

Do insiders and institutionals have more ownership in NUVB or MIRM?

Which has stronger earnings and valuation, NUVB or MIRM?

Is NUVB or MIRM more profitable?

Summary

How does Nuvation Bio compare to Spyre Therapeutics?

Which has higher valuation and earnings, NUVB or SYRE?

Is NUVB or SYRE more profitable?

Do insiders & institutionals have more ownership in NUVB or SYRE?

Do analysts rate NUVB or SYRE?

Which has more volatility and risk, NUVB or SYRE?

Does the media prefer NUVB or SYRE?

Summary

How does Nuvation Bio compare to Lantheus?

Does the media prefer NUVB or LNTH?

Do analysts recommend NUVB or LNTH?

Is NUVB or LNTH more profitable?

Do institutionals & insiders have more ownership in NUVB or LNTH?

Which has stronger valuation & earnings, NUVB or LNTH?

Which has more risk and volatility, NUVB or LNTH?

Summary

How does Nuvation Bio compare to PTC Therapeutics?

Which has more volatility and risk, NUVB or PTCT?

Is NUVB or PTCT more profitable?

Do analysts recommend NUVB or PTCT?

Do insiders & institutionals believe in NUVB or PTCT?

Does the media prefer NUVB or PTCT?

Which has better earnings & valuation, NUVB or PTCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVB vs. The Competition

Nuvation Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools